Press Release: So-Young Reports Unaudited Second Quarter 2026 Financial Results

Dow Jones
Aug 31

BEIJING, Aug. 31, 2026 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

   -- Total revenues were RMB505.2 million (US$74.5 million[1]), an increase of 
      33.4% from RMB378.7 million in the corresponding period of 2025. The 
      aesthetic treatment services revenues were RMB331.4 million (US$48.8 
      million), an increase of 129.5% from RMB144.4 million in the 
      corresponding period of 2025, exceeding the high end of guidance. 
 
   -- Net loss attributable to So-Young International Inc. was RMB22.7 million 
      (US$3.3 million), compared with net loss attributable to So-Young 
      International Inc. of RMB36.0 million in the same period of 2025. 
 
   -- Non-GAAP net loss attributable to So-Young International Inc.[2] was 
      RMB21.0 million (US$3.1 million), compared with non-GAAP net loss 
      attributable to So-Young International Inc. of RMB30.5 million in the 
      same period of 2025. 

Second Quarter 2026 Operational Highlights

   -- The number of verified treatment visits to the branded aesthetic centers 
      for the quarter reached approximately 165,200, an increase of 145% from 
      approximately 67,400 in the same period of 2025. The number of verified 
      aesthetic treatments performed surpassed 362,300, an increase of 134% 
      from approximately 154,500 in the same period of 2025. 
 
   -- The number of active users, defined as those who visited branded 
      aesthetic centers at least once during the 12-month period ended on June 
      30, 2026, exceeded 255,300, an increase of 154% from 100,400 users during 
      the corresponding period in 2025. 
 
   -- The number of core members[3] grew by over 15,000 during the quarter, 
      representing a sequential increase of approximately 24%. These core 
      members contributed over 80% of aesthetic treatment services revenues, 
      with a quarterly repurchase rate of nearly 70%. 
 
   -- As of June 30, 2026, So-Young had 65 fully operational branded aesthetic 
      centers (63 directly-operated, 2 franchised) across eighteen major 
      cities: Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, 
      Chongqing, Ningbo, Changsha, Tianjin, Xi'an, Suzhou, Hefei, Kunming, 
      Nanjing, Jinan, and Foshan. Among them, 47 centers achieved 
      profitability* in the second quarter of 2026. In addition, 51 centers 
      generated positive quarterly operating cash flow* in the second quarter 
      of 2026. Same-store sales growth** in this quarter was 52%, compared to 
      14% in the same quarter of 2025. 
 
([1]) This press release contains translations of certain Renminbi (RMB) 
amounts into U.S. dollars (US$) solely for the convenience of the reader. 
Unless otherwise specified, all translations of Renminbi amounts into U.S. 
dollar amounts in this press release are made at RMB6.7851 to US$1.00, which 
was the U.S. dollars middle rate announced by the Board of Governors of the 
Federal Reserve System of the United States on June 30, 2026. 
([2]) Non-GAAP net loss attributable to So-Young International Inc. is defined 
as net loss attributable to So-Young International Inc. excluding share-based 
compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at 
the end of this press release. 
([3]) We categorize our user base across nine tiers (L0 through L8). Core 
members represent users at Tier L3 and above. 
 
* Center-level profitability measures whether an individual aesthetic center 
achieved positive profit in a given period. It is calculated by deducting 
consumable materials costs, personnel costs, center rental expenses, center 
depreciation expenses, and other center-level operating costs from the 
company's self-operated store revenues, before allocation of any back-office 
or mid-office expenses. Quarterly operating cash flow refers to total cash 
collected from orders less center-level operating payments in a given period, 
and excluding operating expense payments made by back-office or mid-office 
departments during the same period. Center-level profitability and quarterly 
operating cash flow are metrics derived from the Company's internal management 
accounts, which have not been audited. 
** Same-store sales growth represents the year-over-year growth in quarterly 
revenue from stores that are comparable and continuously operated during both 
the current quarter and the same quarter of the prior year. 
 

Management Commentary

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "Our sustained focus on scale and efficiency yielded another strong quarter for our core aesthetic treatment business. Supported by enhanced medical capabilities, a robust standardized delivery system, and deeper AI integration, we scaled our business more efficiently. This solid execution is validated by a 129.5% year-over-year increase in second-quarter aesthetic treatment services revenues with a 3.8 percentage-point expansion in segment gross margin. Going forward, we will further strengthen our supply chain and accelerate AI-powered transformation to deliver more competitive products and services across our expanding network, laying a solid foundation for sustainable, high-quality growth."

Ms. Shannon Shen, Chief Financial Officer of So-Young, added, "In the second quarter of 2026, our aesthetic treatment business exceeded RMB330 million in revenue, representing approximately 130% year-over-year growth and marking the tenth consecutive quarter of triple-digit expansion. This strong performance propelled our second-quarter total revenues to an all-time high of RMB505.2 million, up 33.4% year-over-year. While maintaining this rapid topline growth, we have remained highly focused on expansion quality and sustainability, striving for healthier unit economics and narrowing net loss attributable to the Company by 37.0% year-over-year. These results reaffirmed both our market insights and execution excellence, as we continued to enhance our medical service delivery, organizational capabilities, and supply chain management, while improving operational efficiency. Looking ahead, we see a clear path toward profitability as our industry leadership solidifies and economies of scale continue to unfold."

Second Quarter 2026 Financial Results

Revenues

Total revenues were RMB505.2 million (US$74.5 million), an increase of 33.4% from RMB378.7 million in the same period of 2025. The increase was primarily due to business expansion of the branded aesthetic centers.

   -- Aesthetic treatment services revenues were RMB331.4 million (US$48.8 
      million), an increase of 129.5% from RMB144.4 million in the same period 
      of 2025. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Information and reservation services revenues were RMB87.9 million 
      (US$13.0 million), a decrease of 35.0% from RMB135.2 million in the same 
      period of 2025. The decrease was primarily due to a decrease in the 
      number of medical service providers subscribing to information services 
      on So-Young's platform. 
 
   -- Sales of medical products and maintenance services revenues were RMB73.9 
      million (US$10.9 million), a decrease of 2.8% from RMB76.0 million in the 
      same period of 2025, primarily due to a decrease in the order volume of 
      medical equipment. 
 
   -- Other services revenues were RMB12.0 million (US$1.8 million), a decrease 
      of 48.2% from RMB23.2 million in the same period of 2025, primarily due 
      to a decrease in revenues from insurance brokerage services. 

Cost of Revenues

Cost of revenues was RMB282.4 million (US$41.6 million), an increase of 53.0% from RMB184.6 million in the second quarter of 2025. The increase was primarily due to the business expansion of the branded aesthetic centers.

   -- Cost of aesthetic treatment services was RMB238.4 million (US$35.1 
      million), an increase of 118.0% from RMB109.4 million in the second 
      quarter of 2025. The increase was primarily due to the business expansion 
      of the branded aesthetic centers. 
 
   -- Cost of information and reservation services was RMB5.2 million (US$0.8 
      million), a decrease of 68.7% from RMB16.7 million in the second quarter 
      of 2025. The decrease was in line with the decrease in revenue generated 
      from information and reservation services. 
 
   -- Cost of medical products sold and maintenance services was RMB29.9 
      million (US$4.4 million), a decrease of 24.3% from RMB39.5 million in the 
      second quarter of 2025. The decrease was primarily due to a decrease in 
      costs associated with the sales of medical equipment. 
 
   -- Cost of other services was RMB8.9 million (US$1.3 million), a decrease of 
      53.2% from RMB19.0 million in the second quarter of 2025. The decrease 
      was primarily due to a decrease in costs associated with insurance 
      brokerage services. 

Operating Expenses

Total operating expenses were RMB266.5 million (US$39.3 million), an increase of 10.4% from RMB241.3 million in the second quarter of 2025.

   -- Sales and marketing expenses were RMB153.5 million (US$22.6 million), an 
      increase of 16.8% from RMB131.3 million in the second quarter of 2025. 
      The increase was mainly due to higher branding and user acquisition 
      activities expenses and increased payroll costs at the branded aesthetic 
      centers. 
 
   -- General and administrative expenses were RMB88.6 million (US$13.1 
      million), an increase of 12.5% from RMB78.8 million in the second quarter 
      of 2025. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Research and development expenses were RMB24.4 million (US$3.6 million), 
      a decrease of 21.7% from RMB31.2 million in the second quarter of 2025. 
      The decrease was primarily attributable to improvements in staff 
      efficiency. 

Income Tax Benefits/(Expenses)

Income tax benefits were RMB2.5 million (US$0.4 million), compared with income tax expenses of RMB1.9 million in the same period of 2025.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB22.7 million (US$3.3 million), compared with a net loss attributable to So-Young International Inc. of RMB36.0 million in the second quarter of 2025.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, was RMB21.0 million (US$3.1 million), compared with RMB30.5 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2025.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.22 (US$0.03) and RMB0.22 (US$0.03), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.35 and RMB0.35, respectively, in the same period of 2025.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of June 30, 2026, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB848.2 million (US$125.0 million), compared with RMB936.4 million as of December 31, 2025.

Business Outlook

For the third quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB352.0 million (US$51.9 million) and RMB362.0 million (US$53.4 million), representing a 91.7% to 97.2% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP loss from operations and non-GAAP net loss attributable to So-Young International Inc. by excluding share-based compensation expenses from loss from operations and net loss attributable to So-Young International Inc., respectively.

The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses are non-cash in nature. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Monday, August 31, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 
International:   +1-412-902-4272 
China:           4001-201203 
US:              +1-888-346-8982 
Hong Kong:       +852-800-905945 
Passcode:        So Young 
 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, September 7, 2026. The dial-in details are:

 
International:   +1-412-317-0088 
US:              +1-855-669-9658 
Passcode:        1697226 
 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

Christensen

Ms. Joanna Quan

Phone: +86-10-5900-1548

E-mail: sy@christensencomms.com

 
                       SO-YOUNG INTERNATIONAL INC. 
             UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS 
       (Amounts in thousands, except for share and per share data) 
 
                                                     As of 
                                      ------------------------------------ 
                                      December 31,   June 30,    June 30, 
                                          2025         2026        2026 
                                      ------------  -----------  --------- 
                                          RMB           RMB         US$ 
Assets 
Current assets: 
Cash and cash equivalents                  418,213      442,584     65,229 
Restricted cash and term deposits           64,683       63,450      9,351 
Trade receivables                           51,532       40,344      5,946 
Inventories                                233,389      253,584     37,374 
Receivables from online payment 
 platforms                                  16,296       25,049      3,692 
Amounts due from related parties               774          756        111 
Term deposits and short-term 
 investments                               453,472      342,137     50,425 
Prepayment and other current assets        246,237      296,241     43,661 
                                      ------------  -----------  --------- 
Total current assets                     1,484,596    1,464,145    215,789 
                                      ------------  -----------  --------- 
Non-current assets: 
Long-term investments                      274,753      277,236     40,860 
Intangible assets                          144,097      133,596     19,690 
Goodwill                                       684          684        101 
Property and equipment, net                293,560      336,054     49,528 
Deferred tax assets                         69,313       70,602     10,405 
Operating lease right-of-use assets        251,635      257,343     37,928 
Other non-current assets                   130,998      138,995     20,485 
                                      ------------  -----------  --------- 
Total non-current assets                 1,165,040    1,214,510    178,997 
                                      ------------  -----------  --------- 
Total assets                             2,649,636    2,678,655    394,786 
                                      ============  ===========  ========= 
 
Liabilities 
Current liabilities: 
Short-term borrowings                       39,814      113,141     16,675 
Taxes payable                               43,461       34,504      5,085 
Contract liabilities                        65,948       62,287      9,180 
Salary and welfare payables                130,170      132,791     19,571 
Amounts due to related parties                 618          510         75 
Accrued expenses and other current 
 liabilities                               427,507      482,310     71,084 
Operating lease liabilities-current         76,536       81,593     12,025 
                                      ------------  -----------  --------- 
Total current liabilities                  784,054      907,136    133,695 
                                      ------------  -----------  --------- 
Non-current liabilities: 
Operating lease liabilities-non 
 current                                   183,364      183,551     27,052 
Deferred tax liabilities                    10,615        7,632      1,125 
Other non-current liabilities                2,783        3,987        588 
                                      ------------  -----------  --------- 
Total non-current liabilities              196,762      195,170     28,765 
                                      ------------  -----------  --------- 
Total liabilities                          980,816    1,102,306    162,460 
                                      ============  ===========  ========= 
 
Shareholders' equity: 
Treasury stock                           (391,944)    (391,944)   (57,765) 
Class A ordinary shares (US$0.0005 
 par value; 750,000,000   shares 
 authorized as of December 31, 2025 
 and June 30,   2026; 79,016,808 and 
 65,089,482 shares issued and 
   outstanding as of December 31, 
 2025, 79,322,924 and   65,395,598 
 shares issued and outstanding as of 
 June 30,   2026, respectively)                257          258         38 
Class B ordinary shares (US$0.0005 
 par value; 20,000,000   shares 
 authorized as of December 31, 2025 
 and June 30,   2026; 12,000,000 
 shares issued and outstanding as of 
   December 31, 2025 and June 30, 
 2026)                                          37           37          5 
Additional paid-in capital               3,059,764    3,064,102    451,593 
Statutory reserves                          46,448       46,448      6,846 
Accumulated deficit                    (1,174,587)  (1,246,455)  (183,705) 
Accumulated other comprehensive 
 income                                     13,340     (11,524)    (1,698) 
                                      ------------  -----------  --------- 
Total So-Young International Inc. 
 shareholders' equity                    1,553,315    1,460,922    215,314 
                                      ------------  -----------  --------- 
Non-controlling interests                  115,505      115,427     17,012 
Total shareholders' equity               1,668,820    1,576,349    232,326 
                                      ------------  -----------  --------- 
Total liabilities and shareholders' 
 equity                                  2,649,636    2,678,655    394,786 
                                      ============  ===========  ========= 
 
 
                             SO-YOUNG INTERNATIONAL INC. 
              UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
             (Amounts in thousands, except for share and per share data) 
 
                        For the Three Months Ended       For the Six Months Ended 
                      ------------------------------  ------------------------------ 
                      June 30,   June 30,   June 30,  June 30,   June 30,   June 30, 
                         2025       2026      2026       2025       2026      2026 
                      ---------  ---------  --------  ---------  ---------  -------- 
                         RMB        RMB       US$        RMB        RMB       US$ 
 
Revenues: 
Aesthetic treatment 
 services               144,390    331,435    48,847    243,217    613,867    90,473 
Information and 
 reservation 
 services               135,172     87,916    12,957    256,797    168,227    24,794 
Sales of medical 
 products and 
 maintenance 
 services                76,036     73,877    10,888    131,626    131,018    19,310 
Other services           23,150     12,000     1,769     44,378     24,891     3,668 
                      ---------  ---------  --------  ---------  ---------  -------- 
Total revenues          378,748    505,228    74,461    676,018    938,003   138,245 
Cost of revenues: 
Cost of aesthetic 
 treatment services   (109,370)  (238,384)  (35,133)  (189,634)  (444,142)  (65,458) 
Cost of information 
 and reservation 
 services              (16,705)    (5,224)     (770)   (40,002)   (11,625)   (1,713) 
Cost of medical 
 products sold and 
 maintenance 
 services              (39,491)   (29,880)   (4,404)   (69,916)   (60,283)   (8,885) 
Cost of other 
 services              (18,992)    (8,886)   (1,310)   (36,421)   (17,322)   (2,553) 
                      ---------  ---------  --------  ---------  ---------  -------- 
Total cost of 
 revenues             (184,558)  (282,374)  (41,617)  (335,973)  (533,372)  (78,609) 
                      ---------  ---------  --------  ---------  ---------  -------- 
Gross profit            194,190    222,854    32,844    340,045    404,631    59,636 
Operating expenses: 
Sales and marketing 
 expenses             (131,333)  (153,460)  (22,617)  (229,209)  (284,286)  (41,899) 
General and 
 administrative 
 expenses              (78,786)   (88,617)  (13,061)  (138,070)  (173,121)  (25,515) 
Research and 
 development 
 expenses              (31,177)   (24,403)   (3,597)   (63,286)   (48,742)   (7,184) 
                      ---------  ---------  --------  ---------  ---------  -------- 
Total operating 
 expenses             (241,296)  (266,480)  (39,275)  (430,565)  (506,149)  (74,598) 
                      ---------  ---------  --------  ---------  ---------  -------- 
Loss from operations   (47,106)   (43,626)   (6,431)   (90,520)  (101,518)  (14,962) 
Other 
income/(expenses): 
Investment income, 
 net                        884      4,483       661         99      4,689       691 
Interest income, net      7,948      2,550       376     14,973      6,284       926 
Exchange gains              701      6,345       935        726     11,255     1,659 
Share of losses of 
 equity method 
 investee               (1,012)      (178)      (26)    (3,454)      (365)      (54) 
Others, net               5,663      3,274       483     10,497      1,545       228 
                      ---------  ---------  --------  ---------  ---------  -------- 
Loss before tax        (32,922)   (27,152)   (4,002)   (67,679)   (78,110)  (11,512) 
Income tax 
 (expenses)/benefits    (1,877)      2,453       362      (272)      3,206       473 
                      ---------  ---------  --------  ---------  ---------  -------- 
Net loss               (34,799)   (24,699)   (3,640)   (67,951)   (74,904)  (11,039) 
Net (income)/loss 
 attributable to 
 noncontrolling 
 interests              (1,240)      2,007       296    (1,226)      3,036       447 
Net loss 
 attributable to 
 So-Young 
 International Inc.    (36,039)   (22,692)   (3,344)   (69,177)   (71,868)  (10,592) 
                      =========  =========  ========  =========  =========  ======== 
 
 
 
                                SO-YOUNG INTERNATIONAL INC. 
           UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued) 
                (Amounts in thousands, except for share and per share data) 
 
                         For the Three Months Ended           For the Six Months Ended 
                     ----------------------------------  ---------------------------------- 
                      June 30,    June 30,    June 30,    June 30,    June 30,    June 30, 
                        2025        2026        2026        2025        2026        2026 
                     ----------  ----------  ----------  ----------  ----------  ---------- 
                        RMB         RMB         US$         RMB         RMB         US$ 
 
Net loss per 
ordinary share 
Net loss per 
 ordinary share 
 attributable to 
 ordinary 
 shareholder - 
 basic                   (0.46)      (0.29)      (0.04)      (0.88)      (0.92)      (0.14) 
Net loss per 
 ordinary share 
 attributable to 
 ordinary 
 shareholder - 
 diluted                 (0.46)      (0.29)      (0.04)      (0.88)      (0.92)      (0.14) 
Net loss per ADS 
 attributable to 
 ordinary 
 shareholders - 
 basic (13 ADS 
 represents   10 
 Class A ordinary 
 shares)                 (0.35)      (0.22)      (0.03)      (0.68)      (0.71)      (0.10) 
Net loss per ADS 
 attributable to 
 ordinary 
 shareholders - 
 diluted (13 ADS 
   represents 10 
 Class A ordinary 
 shares)                 (0.35)      (0.22)      (0.03)      (0.68)      (0.71)      (0.10) 
Weighted average 
 number of ordinary 
 shares used in 
 computing loss per 
 share,   basic*     77,826,404  77,781,549  77,781,549  78,194,634  77,726,350  77,726,350 
Weighted average 
 number of ordinary 
 shares used in 
 computing loss per 
 share,   diluted*   77,826,404  77,781,549  77,781,549  78,194,634  77,726,350  77,726,350 
 
Share-based 
compensation 
expenses included 
in: 
Cost of revenues          (124)          --          --       (154)         (3)          -- 
Sales and marketing 
 expenses                 (598)       (228)        (34)       (728)       (315)        (46) 
General and 
 administrative 
 expenses               (4,286)     (1,336)       (197)     (5,690)     (3,816)       (562) 
Research and 
 development 
 expenses                 (487)       (149)        (22)       (580)       (184)        (27) 
 
* Both Class A and Class B ordinary shares are included in the calculation of the weighted 
average number of ordinary shares outstanding, basic and diluted. 
 
 
                        SO-YOUNG INTERNATIONAL INC. 
                Reconciliation of GAAP and Non-GAAP Results 
        (Amounts in thousands, except for share and per share data) 
 
                For the Three Months Ended     For the Six Months Ended 
                ---------------------------  ----------------------------- 
                                     June 
                June 30,  June 30,    30,    June 30,  June 30,   June 30, 
                  2025      2026     2026      2025       2026      2026 
                --------  --------  -------  --------  ---------  -------- 
                  RMB       RMB       US$      RMB        RMB       US$ 
 
GAAP loss from 
 operations     (47,106)  (43,626)  (6,431)  (90,520)  (101,518)  (14,962) 
Add back: 
 Share-based 
 compensation 
 expenses          5,495     1,713      253     7,152      4,318       635 
                --------  --------  -------  --------  ---------  -------- 
 
Non-GAAP loss 
 from 
 operations     (41,611)  (41,913)  (6,178)  (83,368)   (97,200)  (14,327) 
                ========  ========  =======  ========  =========  ======== 
 
 
GAAP net loss 
 attributable 
 to So-Young 
 International 
 Inc.           (36,039)  (22,692)  (3,344)  (69,177)   (71,868)  (10,592) 
Add back: 
 Share-based 
 compensation 
 expenses          5,495     1,713      253     7,152      4,318       635 
                --------  --------  -------  --------  ---------  -------- 
Non-GAAP net 
 loss 
 attributable 
 to So-Young 
 International 
 Inc.           (30,544)  (20,979)  (3,091)  (62,025)   (67,550)   (9,957) 
                ========  ========  =======  ========  =========  ======== 
 

View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-second-quarter-2026-financial-results-302864843.html

SOURCE So-Young International Inc.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10